Shuttle Pharmaceuticals (NASDAQ:SHPH) Posts Quarterly Earnings Results

Shuttle Pharmaceuticals (NASDAQ:SHPH) issued its earnings results on Thursday. The company reported ($1.05) earnings per share (EPS) for the quarter, FiscalAI reports.

Shuttle Pharmaceuticals Stock Performance

Shares of NASDAQ:SHPH traded down $0.13 during mid-day trading on Thursday, reaching $2.38. 35,643 shares of the company’s stock were exchanged, compared to its average volume of 157,229. Shuttle Pharmaceuticals has a twelve month low of $2.25 and a twelve month high of $27.70. The business’s fifty day moving average price is $3.58 and its 200-day moving average price is $4.05. The firm has a market capitalization of $2.55 million, a price-to-earnings ratio of -0.05 and a beta of -1.01.

Analyst Ratings Changes

SHPH has been the subject of a number of recent analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Shuttle Pharmaceuticals in a research report on Tuesday, October 14th. Wall Street Zen upgraded Shuttle Pharmaceuticals to a “sell” rating in a report on Saturday, November 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .